Published • loading... • Updated
Pfizer Posts Strong First-Quarter, Sees Boost From Recent Legal Wins
Higher sales of Eliquis and Vyndamax helped offset a 59% drop in Comirnaty sales, while Pfizer kept its full-year forecast unchanged.
- Pfizer reported first-quarter revenue of $14.5 billion on Tuesday, beating Wall Street expectations of $13.8 billion, and reaffirmed its full-year 2026 outlook of $59.5 billion to $62.5 billion.
- The drugmaker is working to reignite growth as demand for COVID-19 products fades and top-selling drugs face patent expirations, prompting the $10 billion acquisition of obesity drugmaker Metsera.
- Sales of blood thinner Eliquis reached $2.17 billion, while heart drug Vyndamax generated $1.6 billion; the company also secured a favorable European court ruling on COVID vaccines and settled Vyndamax patent disputes last week.
- CEO Albert Bourla said Pfizer expects to return to stronger growth after 2028, driven by obesity drugs in development, and noted the company was surprised by the size of the international weight-loss market.
- J.P. Morgan analyst Chris Schott cautioned that investors need to see more clinical data before sentiment improves, noting Pfizer's first obesity drug from Metsera would not reach the market before 2028.
Insights by Ground AI
Podcasts & Opinions
13 Articles
13 Articles
Pfizer beats Q1 profit estimates on older drugs demand
Pfizer has today posted better than expected quarterly earnings and said a recent favourable European court ruling on its Covid-19 vaccine and patent extension for its heart drug Vyndamax would help secure stronger growth after 2028.
·Ireland
Read Full Article
The American pharmaceutical company recorded revenues of US$14.4 billion between January and March, a 5% increase over the same period in 2025.
·Brazil
Read Full Article
Coverage Details
Total News Sources13
Leaning Left3Leaning Right1Center2Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
